化学抗原受体细胞作为在固体癌症治疗中局部传递TNFα的工具
Zhenqiang Yao1, Chutamath Sittplangkoon1
1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rocheter, NY, USA.
Human vaccines & immunotherapeutics
|October 21, 2025
概括
将TNFα工程免疫细胞与IAP抗体结合起来,为克服固体瘤抵抗提供了一种新的策略. 这种方法旨在增强癌细胞亡,同时减轻细胞因子释放综合征 (CRS) 的副作用.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 化学抗原受体 (CAR) -T细胞在血液癌症中表现出有效性,但在固体瘤中没有.
- 卡-T细胞可能会导致严重的副作用,如细胞因子释放综合征 (CRS).
- 瘤亡因子-α (TNFα) 诱导了亡,但受到亡蛋白抑制剂 (IAP) 的限制.
研究的目的:
- 为了审查TNFα诱导的亡信号.
- 概述了表达TNFα的CAR-T细胞,CAR-巨细胞和CAR-状细胞的设计原理.
- 探索TNFα表达细胞与IAP抗体的组合,以加强癌症治疗.
主要方法:
- 对TNFα诱导的亡信号通路的审查.
- 设计表达TNFα的采用细胞疗法 (CAR-T,CAR-巨细胞,CAR-树突细胞) 的原则.
- 讨论将TNFα输送与IAP抗剂结合起来.
主要成果:
- 由于IAP的上调,单独的TNFα是不够的.
- 通过工程免疫细胞与IAP抗剂相结合的局部TNFα传递可以克服IAP介导的抗性.
- 在固体瘤治疗中提高疗效的潜力.
结论:
- 提供TNFα的工程免疫细胞,特别是与IAP抗体相结合时,代表了固体瘤治疗的有希望的策略.
- 这种双重方法可能会增强瘤细胞亡并降低治疗耐药性.
- 需要进一步研究IAP抗剂与现有癌症药物的禁忌.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


